Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group.
Krogh M, et al.
Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237.
Melanoma Res. 2016.
PMID: 27076041
Clinical Trial.